CNC

CNC highlights margin recovery, stronger Marketplace results and raised 2026 EPS outlook as cost discipline supports profitability gains.

Centene maintains a Buy rating, reflecting sustained margin improvement, cost control, and capital flexibility supporting a higher valuation multiple. CNC's Q2 adjusted EPS of $2.51 beat estimates by over $1, with operating cash flow up 141% year-over-year to $7.96 billion. Medicaid and Medicare segments show disciplined execution; CNC is prioritizing margin over volume, especially by exiting unprofitable Medicare Advantage plans.

CNC's Q2 earnings and revenues top estimates as stronger premium and service revenues drive results despite lower membership and higher medical costs.

Centene NYSE: CNC raised its full-year 2026 adjusted earnings outlook after reporting second-quarter results that exceeded its prior expectations, supported by Marketplace risk-adjustment developments, stronger Medicare performance and continued progress on Medicaid rates.

Although the revenue and EPS for Centene (CNC) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Centene (CNC) came out with quarterly earnings of $2.51 per share, beating the Zacks Consensus Estimate of $0.89 per share. This compares to a loss of $0.16 per share a year ago.

Health insurer Centene's net income eclipsed $1 billion in the second quarter as the company is getting a better handle on rising costs of people in its commercial and government-subsidized health plans.

Centene lifted its guidance for the year after revenue and profit growth in the second quarter were driven by strength in its core government-sponsored and individual healthcare lines.

-- Second Quarter GAAP Diluted Earnings Per Share of $2.19; Adjusted Diluted Earnings Per Share of $2.51 -- -- Increases 2026 GAAP Diluted EPS Guidance: Greater than $3.11 & Adjusted Diluted EPS Greater than $4.80 -- Commercial HBR of 79.2%, demonstrating significant year-over-year improvement in profitability. Medicare segment HBR of 89.5%, including fundamental outperformance in both Medicare Advantage and PDP.

ST. LOUIS, July 28, 2026 /PRNewswire/ -- Centene Corporation (NYSE: CNC) today announced that Kenneth A. Burdick has retired from the Company's Board of Directors, effective July 28, 2026, and that Paul J.